Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 4/20 | 0.64 |
| ▸ | CTSB | P07858 | 2/20 | 0.64 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.60 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.60 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.60 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.56 |
| ▸ | GNRHR | P30968 | 1/20 | 0.56 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | F13A1 | P00488 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | DPP3 | Q9NY33 | 2/20 | 0.51 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29463717 | 0.91 | CAPN1 (0.63) | CAPN1CTSBNTSR2NTSR1SORT1 | |
| SCHEMBL29463744 | 0.88 | KISS1R (0.60) | CAPN1CTSBNTSR2NTSR1SORT1 | |
| SCHEMBL31332280 | 0.84 | KISS1R (0.64) | NTSR2NTSR1SORT1KISS1RGNRHR | |
| SCHEMBL31331997 | 0.83 | KISS1R (0.62) | NTSR2NTSR1SORT1KISS1RGNRHR | |
| SCHEMBL38652302 | 0.83 | CXCR4 (0.59) | CAPN1CTSBNTSR2NTSR1SORT1 | |
| SCHEMBL29716634 | 0.83 | NTSR2 (0.75) | NTSR2NTSR1SORT1GNRHRABCC2 | |
| SCHEMBL30659714 | 0.83 | CAPN1 (0.66) | CAPN1CTSBNTSR2NTSR1SORT1 | |
| SCHEMBL29598567 | 0.82 | KISS1R (0.65) | NTSR2NTSR1KISS1RTACR1C5AR1 | |
| SCHEMBL32681271 | 0.82 | DPP3 (0.66) | CAPN1CTSBNTSR2NTSR1SORT1 | |
| SCHEMBL29772142 | 0.82 | KISS1R (0.64) | NTSR2NTSR1SORT1KISS1RABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118557735-A | Application of NRP1 inhibitor in preparation of anti-vascular calcification medicine | 中山大学附属第八医院（深圳福田） | 2024-08-30 | — | — | CN | claimed |
| CN-117562995-A | Nanometer medicine for synergistic chemophotothermal therapy and targeted treatment of endometriosis and preparation method thereof | 无锡市中医医院 | 2024-02-20 | — | — | CN | claimed |
| CN-116688164-A | Radionuclide-labeled A7R polypeptides D A7R polypeptide and application thereof | 上海市第一人民医院 | 2023-09-05 | — | — | CN | claimed |
| CN-115518152-B | Polypeptide micelle for enhancing light immunotherapy based on tumor vascular normalization and immune checkpoint blocking and preparation and application thereof | 中山大学 | 2023-09-01 | — | — | CN | claimed |
| CN-115611988-A | Compounds for targeted immunotherapy | 博笛生物科技有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-115518152-A | Polypeptide micelle for enhancing photoimmunotherapy based on tumor blood vessel normalization and immune checkpoint blockade coordination, and preparation and application thereof | 中山大学 | 2022-12-27 | — | — | CN | claimed |
| CN-115521369-A | Biomarker NRP1 and application thereof in diagnosis, prevention and treatment of pulmonary fibrosis and asthma | 上海市免疫学研究所 | 2022-12-27 | — | — | CN | claimed |
| CN-115337402-A | Combination therapeutic compositions and combination therapeutic methods for treating cancer | 博笛生物科技有限公司 | 2022-11-15 | — | — | CN | claimed |
| US-20220322945-A1 | USE OF FLUOROPHORE COMPOUNDS OF THE AZA- BODIPY TYPE AS CONTRAST AGENTS IN THE SHORT WAVE INFRARED REGION | INSERM - INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (FR) | 2022-10-13 | — | — | US | claimed |
| EP-4010434-A1 | USE OF FLUOROPHORE COMPOUNDS OF THE AZA-BODIPY TYPE AS CONTRAST AGENTS IN THE SHORT WAVE INFRARED REGION | UNIVERSITE GRENOBLE ALPES (FR) | 2022-06-15 | — | — | EP | claimed |
| CN-114450353-A | Use of aza-fluoroboro-fluorescent fluorophore compounds as contrast agents in the short-wave infrared region | 阿尔卑斯格勒诺布尔大学 | 2022-05-06 | — | — | CN | claimed |
| CN-122031708-A | Cascade double-and logic DNA nano circuit and preparation method and application thereof | 南方医科大学珠江医院 | 2026-05-15 | — | — | CN | disclosed |
| CN-121971585-A | Application of micromolecular drug ATWLPPR PEPTIDE TFA in resisting mycobacterium bovis infection | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 2026-05-05 | — | — | CN | disclosed |
| CN-121971585-A | Application of micromolecular drug ATWLPPR PEPTIDE TFA in resisting mycobacterium bovis infection | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 2026-05-05 | — | — | CN | disclosed |
| US-12590122-B2 | NRP-1 binding inhibitory peptides and uses thereof | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-03-31 | — | — | US | disclosed |
| US-20220064671-A1 | METHODS AND SYSTEMS FOR PRODUCING AAV PARTICLES | VOYAGER THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| US-11260133-B2 | Methods and compositions related to peptides and proteins with C-terminal elements | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2022-03-01 | — | — | US | disclosed |
| US-11260032-B2 | Method for preparing biofilm-coated drug nanocrystal and application thereof | Shanghai Whittlong Pharmaceutical Institute (CN) | 2022-03-01 | — | — | US | disclosed |
| WO-2022026409-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS RELATED TO GLUCOSYLCERAMIDASE BETA DEFICIENCY | VOYAGER THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022026410-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NIEMANN-PICK TYPE C1 DISEASE | VOYAGER THERAPEUTICS, INC (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11260133-B2 | Methods and compositions related to peptides and proteins with C-terminal elements | CD2BP2, CLTC, CLTA | CAPN1 444/4885CTSB 331/4885NTSR2 674/4885 |
| US-12590122-B2 | NRP-1 binding inhibitory peptides and uses thereof | NRP1, FLT1, KDR | CAPN1 2238/4885CTSB 3288/4885NTSR2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.